<?xml version='1.0' encoding='utf-8'?>
<document id="23703578"><sentence text="Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors." /><sentence text="The HMG-CoA reductase inhibitors are a class of drugs also known as statins" /><sentence text=" These drugs are effective and widely prescribed for the treatment of hypercholesterolemia and prevention of cardiovascular morbidity and mortality" /><sentence text=" Seven statins are currently available: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin"><entity charOffset="40-52" id="DDI-PubMed.23703578.s4.e0" text="atorvastatin" /><entity charOffset="54-65" id="DDI-PubMed.23703578.s4.e1" text="fluvastatin" /><entity charOffset="67-77" id="DDI-PubMed.23703578.s4.e2" text="lovastatin" /><entity charOffset="79-91" id="DDI-PubMed.23703578.s4.e3" text="pitavastatin" /><entity charOffset="93-104" id="DDI-PubMed.23703578.s4.e4" text="pravastatin" /><entity charOffset="106-118" id="DDI-PubMed.23703578.s4.e5" text="rosuvastatin" /><entity charOffset="123-134" id="DDI-PubMed.23703578.s4.e6" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e0" e2="DDI-PubMed.23703578.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e0" e2="DDI-PubMed.23703578.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e0" e2="DDI-PubMed.23703578.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e0" e2="DDI-PubMed.23703578.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e0" e2="DDI-PubMed.23703578.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e0" e2="DDI-PubMed.23703578.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e0" e2="DDI-PubMed.23703578.s4.e6" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e1" e2="DDI-PubMed.23703578.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e1" e2="DDI-PubMed.23703578.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e1" e2="DDI-PubMed.23703578.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e1" e2="DDI-PubMed.23703578.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e1" e2="DDI-PubMed.23703578.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e1" e2="DDI-PubMed.23703578.s4.e6" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e2" e2="DDI-PubMed.23703578.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e2" e2="DDI-PubMed.23703578.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e2" e2="DDI-PubMed.23703578.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e2" e2="DDI-PubMed.23703578.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e2" e2="DDI-PubMed.23703578.s4.e6" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e3" e2="DDI-PubMed.23703578.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e3" e2="DDI-PubMed.23703578.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e3" e2="DDI-PubMed.23703578.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e3" e2="DDI-PubMed.23703578.s4.e6" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e4" e2="DDI-PubMed.23703578.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e4" e2="DDI-PubMed.23703578.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e4" e2="DDI-PubMed.23703578.s4.e6" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e5" e2="DDI-PubMed.23703578.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23703578.s4.e5" e2="DDI-PubMed.23703578.s4.e6" /></sentence><sentence text=" Although these drugs are generally well tolerated, skeletal muscle abnormalities from myalgia to severe lethal rhabdomyolysis can occur" /><sentence text=" Factors that increase statin concentrations such as drug-drug interactions can increase the risk of these adverse events" /><sentence text=" Drug-drug interactions are dependent on statins' pharmacokinetic profile: simvastatin, lovastatin and atorvastatin are metabolized through cytochrome P450 (CYP) 3A, while the metabolism of the other statins is independent of this CYP"><entity charOffset="75-86" id="DDI-PubMed.23703578.s7.e0" text="simvastatin" /><entity charOffset="88-98" id="DDI-PubMed.23703578.s7.e1" text="lovastatin" /><entity charOffset="103-115" id="DDI-PubMed.23703578.s7.e2" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.23703578.s7.e0" e2="DDI-PubMed.23703578.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23703578.s7.e0" e2="DDI-PubMed.23703578.s7.e1" /><pair ddi="false" e1="DDI-PubMed.23703578.s7.e0" e2="DDI-PubMed.23703578.s7.e2" /><pair ddi="false" e1="DDI-PubMed.23703578.s7.e1" e2="DDI-PubMed.23703578.s7.e1" /><pair ddi="false" e1="DDI-PubMed.23703578.s7.e1" e2="DDI-PubMed.23703578.s7.e2" /></sentence><sentence text=" All statins are substrate of organic anion transporter polypeptide 1B1, an uptake transporter expressed in hepatocyte membrane that may also explain some drug-drug interactions" /><sentence text=" Many HIV-infected patients have dyslipidemia and comorbidities that may require statin treatment" /><sentence text=" HIV-protease inhibitors (HIV PIs) are part of recommended antiretroviral treatment in combination with two reverse transcriptase inhibitors" /><sentence text=" All HIV PIs except nelfinavir are coadministered with a low dose of ritonavir, a potent CYP3A inhibitor to improve their pharmacokinetic properties"><entity charOffset="20-30" id="DDI-PubMed.23703578.s11.e0" text="nelfinavir" /><entity charOffset="69-78" id="DDI-PubMed.23703578.s11.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.23703578.s11.e0" e2="DDI-PubMed.23703578.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23703578.s11.e0" e2="DDI-PubMed.23703578.s11.e1" /></sentence><sentence text=" Cobicistat is a new potent CYP3A inhibitor that is combined with elvitegravir and will be combined with HIV-PIs in the future"><entity charOffset="66-78" id="DDI-PubMed.23703578.s12.e0" text="elvitegravir" /></sentence><sentence text=" The HCV-PIs boceprevir and telaprevir are both, to different extents, inhibitors of CYP3A"><entity charOffset="13-23" id="DDI-PubMed.23703578.s13.e0" text="boceprevir" /><entity charOffset="28-38" id="DDI-PubMed.23703578.s13.e1" text="telaprevir" /><pair ddi="false" e1="DDI-PubMed.23703578.s13.e0" e2="DDI-PubMed.23703578.s13.e0" /><pair ddi="false" e1="DDI-PubMed.23703578.s13.e0" e2="DDI-PubMed.23703578.s13.e1" /></sentence><sentence text=" This review summarizes the pharmacokinetic properties of statins and PIs with emphasis on their metabolic pathways explaining clinically important drug-drug interactions" /><sentence text=" Simvastatin and lovastatin metabolized through CYP3A have the highest potency for drug-drug interaction with potent CYP3A inhibitors such as ritonavir- or cobicistat-boosted HIV-PI or the hepatitis C virus (HCV) PI, telaprevir or boceprevir, and therefore their coadministration is contraindicated"><entity charOffset="1-12" id="DDI-PubMed.23703578.s15.e0" text="Simvastatin" /><entity charOffset="17-27" id="DDI-PubMed.23703578.s15.e1" text="lovastatin" /><entity charOffset="217-227" id="DDI-PubMed.23703578.s15.e2" text="telaprevir" /><entity charOffset="231-241" id="DDI-PubMed.23703578.s15.e3" text="boceprevir" /><pair ddi="false" e1="DDI-PubMed.23703578.s15.e0" e2="DDI-PubMed.23703578.s15.e0" /><pair ddi="false" e1="DDI-PubMed.23703578.s15.e0" e2="DDI-PubMed.23703578.s15.e1" /><pair ddi="false" e1="DDI-PubMed.23703578.s15.e0" e2="DDI-PubMed.23703578.s15.e2" /><pair ddi="false" e1="DDI-PubMed.23703578.s15.e0" e2="DDI-PubMed.23703578.s15.e3" /><pair ddi="false" e1="DDI-PubMed.23703578.s15.e1" e2="DDI-PubMed.23703578.s15.e1" /><pair ddi="false" e1="DDI-PubMed.23703578.s15.e1" e2="DDI-PubMed.23703578.s15.e2" /><pair ddi="false" e1="DDI-PubMed.23703578.s15.e1" e2="DDI-PubMed.23703578.s15.e3" /><pair ddi="false" e1="DDI-PubMed.23703578.s15.e2" e2="DDI-PubMed.23703578.s15.e2" /><pair ddi="false" e1="DDI-PubMed.23703578.s15.e2" e2="DDI-PubMed.23703578.s15.e3" /></sentence><sentence text=" Atorvastatin is also a CYP3A substrate, but less potent drug-drug interactions have been reported with CYP3A inhibitors"><entity charOffset="1-13" id="DDI-PubMed.23703578.s16.e0" text="Atorvastatin" /></sentence><sentence text=" Non-CYP3A-dependent statin concentrations are also affected although to a lesser extent when coadministered with HIV or HCV PIs, mainly through interaction with OATP1B1, and treatment should start with the lowest available statin dose" /><sentence text=" Effectiveness and occurrence of adverse effects should be monitored at regular time intervals" /><sentence text=" " /></document>